bioAffinity Technologies, Inc. (BIAF)
USD 0.53
(-4.64%)
USD 0.53
(-4.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.24 Million USD | 88.86% |
| 2022 | -11.16 Million USD | -211.58% |
| 2021 | 10 Million USD | 0.81% |
| 2020 | 9.92 Million USD | 189.1% |
| 2019 | 3.43 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 578.69 Thousand USD | 160.38% |
| 2024 Q1 | -958.43 Thousand USD | 22.89% |
| 2023 Q4 | -1.24 Million USD | 55.97% |
| 2023 FY | -1.24 Million USD | 88.86% |
| 2023 Q2 | -8.23 Million USD | 14.21% |
| 2023 Q1 | -9.6 Million USD | 13.99% |
| 2023 Q3 | -2.82 Million USD | 65.73% |
| 2022 Q2 | 10.9 Million USD | 0.1% |
| 2022 Q1 | 10.89 Million USD | 8.94% |
| 2022 FY | -11.16 Million USD | -211.58% |
| 2022 Q4 | -11.16 Million USD | 11.99% |
| 2022 Q3 | -12.68 Million USD | -216.27% |
| 2021 Q4 | 10 Million USD | -1.51% |
| 2021 Q1 | 83.1 Thousand USD | -99.16% |
| 2021 Q3 | 10.15 Million USD | 0.0% |
| 2021 FY | 10 Million USD | 0.81% |
| 2020 FY | 9.92 Million USD | 189.1% |
| 2020 Q4 | 9.92 Million USD | 0.0% |
| 2019 FY | 3.43 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 96.85% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 78.983% |
| Aspira Women's Health Inc. | -331 Thousand USD | -275.508% |
| Biodesix, Inc. | 34.3 Million USD | 103.623% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 78.555% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -0.0% |
| Bionano Genomics, Inc. | 34.88 Million USD | 103.563% |
| CareDx, Inc | -47.97 Million USD | 97.409% |
| Check-Cap Ltd. | -24.75 Million USD | 94.979% |
| Castle Biosciences, Inc. | -83.53 Million USD | 98.512% |
| DarioHealth Corp. | -7.54 Million USD | 83.533% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.064% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 98.495% |
| Guardant Health, Inc. | 220.22 Million USD | 100.564% |
| ICON Public Limited Company | 3.56 Billion USD | 100.035% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.252% |
| Illumina, Inc. | 1.21 Billion USD | 100.102% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 77.121% |
| iSpecimen Inc. | -2.14 Million USD | 42.12% |
| Standard BioTools Inc. | 46.5 Million USD | 102.673% |
| MDxHealth SA | 18.88 Million USD | 106.582% |
| 23andMe Holding Co. | -141.37 Million USD | 99.121% |
| Medpace Holdings, Inc. | -103.32 Million USD | 98.797% |
| Myriad Genetics, Inc. | 88.1 Million USD | 101.411% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 455.27% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 49.05% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.462% |
| Neogen Corporation | 735.62 Million USD | 100.169% |
| Inotiv, Inc. | 382.14 Million USD | 100.325% |
| Natera, Inc. | -200.1 Million USD | 99.379% |
| OpGen, Inc. | 11.89 Million USD | 110.452% |
| OPKO Health, Inc. | 230.68 Million USD | 100.539% |
| Psychemedics Corporation | 334 Thousand USD | 472.135% |
| Prenetics Global Limited | -43.33 Million USD | 97.132% |
| Prenetics Global Limited | -43.33 Million USD | 97.132% |
| Precipio, Inc. | -386 Thousand USD | -222.003% |
| Personalis, Inc. | -8.02 Million USD | 84.506% |
| RadNet, Inc. | 1.14 Billion USD | 100.108% |
| Sera Prognostics, Inc. | -2.02 Million USD | 38.53% |
| Sotera Health Company | 2.02 Billion USD | 100.061% |
| Neuronetics, Inc. | 2.79 Million USD | 144.438% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 91.896% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 91.896% |
| Trinity Biotech plc | 63.73 Million USD | 101.95% |
| T2 Biosystems, Inc. | 33.8 Million USD | 103.676% |
| Twist Bioscience Corporation | -192.4 Million USD | 99.354% |
| Exagen Inc. | -12.77 Million USD | 90.268% |